Search Results
Search for other papers by Jonathan Hazlehurst in
Google Scholar
PubMed
Search for other papers by Bernard Khoo in
Google Scholar
PubMed
Department of Medicine, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
Search for other papers by Carolina Brito Lobato in
Google Scholar
PubMed
Search for other papers by Ibiyemi Ilesanmi in
Google Scholar
PubMed
Search for other papers by Sally Abbott in
Google Scholar
PubMed
Search for other papers by Tin Chan in
Google Scholar
PubMed
Search for other papers by Sanesh Pillai in
Google Scholar
PubMed
Search for other papers by Kate Maslin in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK
Search for other papers by Sanjay Purkayastha in
Google Scholar
PubMed
Search for other papers by Barbara McGowan in
Google Scholar
PubMed
Search for other papers by Rob Andrews in
Google Scholar
PubMed
Search for other papers by Eveleigh Nicholson in
Google Scholar
PubMed
Search for other papers by Katherine McCullough in
Google Scholar
PubMed
Search for other papers by Lorraine Albon in
Google Scholar
PubMed
Search for other papers by Rachel Batterham in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Shareen Forbes in
Google Scholar
PubMed
Search for other papers by Gavin Bewick in
Google Scholar
PubMed
Search for other papers by Tricia M-M Tan in
Google Scholar
PubMed
meal test; OGTT, oral glucose tolerance test; RYGB, Roux-en-Y gastric bypass; SC, subcutaneous. In summary, there is evidence to suggest that short-acting SC octreotide and pasireotide can prevent PBH when given three times a day with meals
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
pegvisomant both improve insulin sensitivity ( 6 ), glucose metabolism may improve or worsen when patients are treated with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide ( 7 , 8 , 9 , 10 ). Pasireotide is a somatostatin